Free Republic 4th Qtr 2024 Fundraising Target: $81,000 Receipts & Pledges to-date: $37,512
46%  
Woo hoo!! And we're now over 46%!! Thank you all very much!! God bless.

Keyword: elevidys

Brevity: Headers | « Text »
  • Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy

    06/22/2024 12:18:08 PM PDT · by george76 · 11 replies
    STAT ^ | June 20, 2024 | Jason Mast and Matthew Herper
    For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official to overrule the prevailing view of their staff and approve a drug for Duchenne muscular dystrophy. On Thursday evening, the FDA announced it expanded the approval of Elevidys, Sarepta’s Duchenne gene therapy, to cover nearly all patients, regardless of age or wheelchair status, despite the fact that the drug failed a large, Phase 3 trial last year. That decision, documents concurrently released by the agency show, was made almost exclusively by Peter Marks, the agency’s director of the Center for Biologics Evaluation and Research. He...